Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer

214Citations
Citations of this article
205Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Sirtuin-3 (SIRT3), a major mitochondria NAD+-dependent deacetylase, may target mitochondrial proteins for lysine deacetylation and also regulate cellular functions. And, SIRT3 is an emerging instrumental regulator of the mitochondrial adaptive response to stress, such as metabolic reprogramming and antioxidant defense mechanisms. Accumulating evidence has recently demonstrated that SIRT3 may function as either oncogene or tumor suppressor on influencing cell death by targeting a series of key modulators and their relevant pathways in cancer. Thus, in this review, we present the structure, transcriptional regulation, and posttranslational modifications of SIRT3. Subsequently, we focus on highlighting the Janus role of SIRT3 with oncogenic or tumor-suppressive function in cancer, which may provide more new clues for exploring SIRT3 as a therapeutic target for drug discovery. © 2014 Macmillan Publishers Limited.

Cite

CITATION STYLE

APA

Chen, Y., Fu, L. L., Wen, X., Wang, X. Y., Liu, J., Cheng, Y., & Huang, J. (2014). Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell Death and Disease, 5(2). https://doi.org/10.1038/cddis.2014.14

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free